/
Oncology
Prostate Cancer
416
Pipeline Programs↗
923
Active Trials↗
225
Companies Involved↗
Prostate Cancer is a highly competitive landscape with 416 programs across 225 companies. The most active players are AstraZeneca, Novartis, Amgen. 78 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical88
Phase 174
Phase 2176
Phase 378
Approved
No programs
Analysis
Modality Breakdown
87%
Small molecule
312 of 360 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 360 classified programs, each share of the total. Modality classified for 91% of 416 pipeline programs.
Analysis
Trial Status
2,952
clinical trials
Completed1,380 · 47%
Recruiting486 · 16%
Terminated354 · 12%
Active, not recruiting293 · 10%
Unknown status160 · 5%
Not yet recruiting130 · 4%
Other149 · 5%
Clinical Trials
Trial Activity
2952 trials
SPECTRA: Intraoperative Hyperspectral Imaging for Prostate Cancer
Recruiting·—·Preclinical·NCT07826858·26 enrolled
Page 1 of 197
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)